Reversible Pathologic and Cognitive Phenotypes in an Inducible Model of Alzheimer-Amyloidosis
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Transgenic mice that express mutant amyloid precursor protein (APPsi) using tet-Off vector systems provide an alternative model for assessing short- and long-term effects of Aβ-targeting therapies on phenotypes related to the deposition of Alzheimer-type amyloid. Here we use such a model, termed APPsi:tTA, to determine what phenotypes persist in mice with high amyloid burden after new production of APP/Aβ has been suppressed. We find that 12- to 13-month-old APPsi:tTA mice are impaired in cognitive tasks that assess short- and long-term memories. Acutely suppressing new APPsi/Aβ production produced highly significant improvements in performing short-term spatial memory tasks, which upon continued suppression translated to superior performance in more demanding tasks that assess long-term spatial memory and working memory. Deficits in episodic-like memory and cognitive flexibility, however, were more persistent. Arresting mutant APPsi production caused a rapid decline in the brain levels of soluble APP ectodomains, full-length APP, and APP C-terminal fragments. As expected, amyloid deposits persisted after new APP/Aβ production was inhibited, whereas, unexpectedly, we detected persistent pools of solubilizable, relatively mobile, Aβ42. Additionally, we observed persistent levels of Aβ-immunoreactive entities that were of a size consistent with SDS-resistant oligomeric assemblies. Thus, in this model with significant amyloid pathology, a rapid amelioration of cognitive deficits was observed despite persistent levels of oligomeric Aβ assemblies and low, but detectable solubilizable Aβ42 peptides. These findings implicate complex relationships between accumulating Aβ and activities of APP, soluble APP ectodomains, and/or APP C-terminal fragments in mediating cognitive deficits in this model of amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data
Ennaceur, A., & Delacour, J. (1988) · Behavioural Brain Research · doi:10.1016/0166-4328(88)90157-x · Cited by 3,223 · cited 1×
“Trial 2 takes advantage of the innate tendency of mice to explore novel areas (Ennaceur and Delacour, 1988), and mice with intact spatial recognition memory will prefer to explore a novel arm over familiar arms, whereas mice with impaired spatial memory will enter all arms equally (Conrad et al.,…”
BackgroundScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 1×
“Early-onset familial AD is also associated with mutations in two functionally related proteins termed presenilin 1 and 2 (Rogaev et al., 1995), which are interchangeable components of -secretase, the multiprotein complex that catalyzes one of the critical proteolytic events that produces A 42 (for…”
BackgroundIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“This longer A peptide is most prone to produce amyloid deposits (Iwatsubo et al., 1994; McGowan et al., 2005).”
BackgroundCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 1×
“…A peptide through a series of proteolytic events (for review, see Lichtenthaler et al., 2011), generally lead to enhanced levels of A 42 peptides (Citron et al., 1992, 1997; Suzuki et al., 1994; Scheuner et al., 1996; Kwok et al., 2000; De Jonghe et al., 2001; Bentahir et al., 2006; Di et al.,…”
BackgroundAβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271 · cited 1×
“…A peptide through a series of proteolytic events (for review, see Lichtenthaler et al., 2011), generally lead to enhanced levels of A 42 peptides (Citron et al., 1992, 1997; Suzuki et al., 1994; Scheuner et al., 1996; Kwok et al., 2000; De Jonghe et al., 2001; Bentahir et al., 2006; Di et al.,…”
BackgroundKawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 1×
“At 16 weeks of age, the levels of A will have begun to rise, indicating that there are beginnings of A assembly into more stable structures (Kawarabayashi et al., 2001).”
BackgroundKayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, J., Breydo, L., Thompson, J. L., et al. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-18 · Cited by 773
A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease
Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., Justice, A., McConlogue, L., Games, D., Freedman, S. B., et al. (2000) · Nature · doi:10.1038/35050103 · Cited by 740
Cited by
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'
Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 662
Practical considerations for choosing a mouse model of Alzheimer’s disease
Jankowsky, J. L., & Zheng, H. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0231-7 · Cited by 449
β-amyloid Peptides and Amyloid Plaques in Alzheimer's Disease
Gouras, G. K., Olsson, T. T., & Hansson, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0313-y · Cited by 325
Amyloid β-protein oligomers and Alzheimer’s disease
Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276
“could be suppressed [25].”
Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190
“Several studies with γ-secretase inhibitors [76-79] and two studies in transgenic mice that overexpress mutant amyloid precursor protein (APP) via a doxycycline-regulated promoter [80,81] show that subchronic or chronic suppression of Aβ production arrested Aβ plaque formation but did not result in observable clearanc…”
Background
Metadata
- Authors
- Melnikova, T., Fromholt, S., Kim, H., Lee, D., Xu, G., Price, A., Moore, B. D., Golde, T. E., Felsenstein, K. M., Savonenko, A., & Borchelt, D. R.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2013-02-27
- Volume
- 33
- Issue
- 9
- Pages
- 3765-3779
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1988053453
- Cited by
- 49
- References
- 20
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reversible Pathologic and Cognitive Phenotypes in an Inducible Model of Alzheimer-Amyloidosis. https://app.cochat.ai/papers/10.1523/jneurosci.4251-12.2013
- The paper
- Melnikova, T., Fromholt, S., Kim, H., Lee, D., Xu, G., Price, A., Moore, B. D., Golde, T. E., Felsenstein, K. M., Savonenko, A., & Borchelt, D. R. (2013). Reversible Pathologic and Cognitive Phenotypes in an Inducible Model of Alzheimer-Amyloidosis. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.4251-12.2013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.